Literature DB >> 17625107

Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.

D S Goldstein1, R Imrich, E Peckham, C Holmes, G Lopez, C Crews, J Hardy, A Singleton, M Hallett.   

Abstract

BACKGROUND: Patients with Parkinson disease (PD) often have cardiac sympathetic denervation and failure of neurocirculatory regulation by baroreflexes. Familial PD caused by mutation of the gene encoding alpha-synuclein or by alpha-synuclein gene triplication also features cardiac sympathetic denervation and baroreflex failure.
METHODS: Here we report results of cardiac sympathetic neuroimaging by 6-[(18)F]fluorodopamine PET, baroreflex testing based on beat-to-beat hemodynamic responses to the Valsalva maneuver, and nigrostriatal neuroimaging using 6-[(18)F] fluorodopa PET in a proband with mutation of the gene encoding leucine-rich repeat kinase 2 (LRRK2), the most common genetic abnormality identified so far in familial PD.
RESULTS: The patient had no detectable 6-[(18)F] fluorodopamine-derived radioactivity in the left ventricular myocardium, a progressive fall in blood pressure during the Valsalva maneuver and no pressure overshoot after release of the maneuver, and decreased 6-[(18)F] fluorodopa-derived radioactivity bilaterally in the putamen and substantia nigra.
CONCLUSION: This patient with Parkinson disease (PD) caused by LRRK2 mutation had evidence of cardiac sympathetic denervation, baroreflex-sympathoneural and baroreflex-cardiovagal failure, and nigrostriatal dopamine deficiency, a pattern resembling that in the sporadic disease. The results fit with the concept that in LRRK2 PD, parkinsonism, cardiac sympathetic denervation, and baroreflex failure can result from a common pathogenetic process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17625107     DOI: 10.1212/01.wnl.0000268696.57912.64

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.

Authors:  Zhenyu Yue
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

3.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

Review 4.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

5.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Authors:  Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2011-08-30       Impact factor: 44.182

Review 6.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

7.  Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.

Authors:  Claudia Carricarte Naranjo; Connie Marras; Naomi P Visanji; David J Cornforth; Lazaro Sanchez-Rodriguez; Birgitt Schüle; Samuel M Goldman; Mario Estévez; Phyllis K Stein; Anthony E Lang; Herbert F Jelinek; Andrés Machado
Journal:  Clin Auton Res       Date:  2019-08-23       Impact factor: 4.435

8.  Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.

Authors:  John D Heiss; Codrin Lungu; Dima A Hammoud; Peter Herscovitch; Debra J Ehrlich; Davis P Argersinger; Sanhita Sinharay; Gretchen Scott; Tianxia Wu; Howard J Federoff; Kareem A Zaghloul; Mark Hallett; Russell R Lonser; Krystof S Bankiewicz
Journal:  Mov Disord       Date:  2019-05-30       Impact factor: 10.338

Review 9.  Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.

Authors:  Zhenyu Yue; M Lenard Lachenmayer
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

Review 10.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.